Randomised multicentre trial of anisoylated plasminogen streptokinase activator complex versus heparin. Interim results.
Meinertz
T
T
Klinikum der Albert-Ludwigs-Universität, Med. Universitäts-Klinik, Abteilung Innere Medizin III, Kardiologie, Freiburg.
Kasper
W
W
D016255:Anistreplase; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D010958:Plasminogen / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D016255:Anistreplase; D010958:Plasminogen; D006493:Heparin; D013300:Streptokinase